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OBJECTIVES To evaluate the corrected Thrombolysis in Myocardial Infarction (TIMI) frame count
(CTFC) as a predictor of late survival after myocardial infarction.
BACKGROUND Thrombolysis in Myocardial Infarction flow grades predict late survival after myocardial
infarction. The CTFC provides a more reproducible measurement of infarct-related artery
blood flow than the TIMI flow grade, and has been linked to 30-day outcomes, but it has not
yet been established how the CTFC correlates with late survival.
METHODS Of 1,001 patients with acute myocardial infarction presenting within 4 h of symptom onset,
882 underwent angiography at approximately three weeks. Infarct artery flow was assessed,
blinded to clinical outcomes, according to the CTFC and TIMI flow grade. Late cardiac
mortality and survival were determined in 97.5% of patients.
RESULTS The mean CTFC was 40 6 29 in 644 patent infarct arteries (median, 34 [interquartile range,
24 to 47]). The CTFC, assessed as a continuous univariate variable, was found to be a
predictor of five-year survival, as was the TIMI flow grade (both p , 0.001). On multivariate
analysis, factors associated with five-year survival included the ejection fraction or end-systolic
volume index (both p , 0.001), exercise duration (p 5 0.005), age (p 5 0.008), diabetes (p 5
0.02) and CTFC (p 5 0.02) or TIMI flow (p 5 0.02). The same factors, except for the
CTFC and TIMI flow grade, were predictors of 10-year survival.
CONCLUSIONS The CTFC three weeks after myocardial infarction was an independent predictor of five-year
survival, but not 10-year survival. Although the CTFC provided additional prognostic
information within TIMI flow grades, its superiority was not demonstrated. (J Am Coll
Cardiol 2000;35:1516–24) © 2000 by the American College of Cardiology
Administration of thrombolytic therapy increases reperfu-
sion, preserves left ventricular function and increases sur-
vival (1–5). Differences in infarct-related artery blood flow,
assessed by Thrombolysis in Myocardial Infarction (TIMI)
flow grading (6) at 90 min, correlated with 30-day mortality
in the Global Use of Strategies to Open Occluded Arteries
(GUSTO-I) trial (2), and may provide a conceptual basis for
determining the relative efficacy of reperfusion therapies for
testing in large clinical trials (7,8).
However, the reproducibility of TIMI flow assessments,
particularly TIMI grade 2 (incomplete reperfusion), has
been questioned (9). The corrected TIMI frame count
(CTFC) is more reproducible than TIMI flow grading (9).
This technique counts the number of cineangiographic
frames from initial contrast opacification of the proximal
coronary artery to opacification of distal arterial landmarks,
and corrects for the length of the left anterior descending
artery and saphenous vein grafts (9,10).
The mean CTFC in the arteries of patients without
infarction is 21 (SD 3) (9,10). Among patients with TIMI
grade 3 flow in the infarct-related artery (i.e., similar flow to
nonculprit arteries), only 50% to 60% have a CTFC of #27,
and 10% to 20% have a CTFCs of $40, as assessed in core
laboratories (9–11). Lower CTFCs at 90 min and four
weeks after the administration of thrombolytic therapy has
been shown to correlate with better ventricular function
(9,11,12), but to our knowledge, there are no data relating
the CTFC to late survival.
In this study, we determined the value of the CTFC and
TIMI flow grade, assessed at three weeks after myocardial
infarction, as predictors of late survival.
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METHODS
Patient population. Patients enrolled in three randomized
controlled trials (4,13,14) of thrombolytic and adjunctive
therapies for acute myocardial infarction were scheduled to
have angiography at three weeks. Patients were eligible if
they presented #4 h after the onset of $30 min of chest
pain with $1 mm of ST-segment elevation in two contig-
uous electrocardiographic leads or $2 mm in two of leads
V1 to V3 (15). The patients were aged #70 years in two
trials (4,13) and #75 years in the third; the exclusion criteria
were as described previously (4,13–16). The trials were
approved by the local ethics committees and written in-
formed consent was obtained from all patients.
Treatment regimen. Details of the thrombolytic regimens
have been reported previously (4,13,14). In brief, 135
patients received recombinant tissue plasminogen activator
(10-mg bolus followed by 50 mg over 1 h and 40 mg over the
next 2 h); 754 patients received intravenous streptokinase
(1.5 mU over 30 to 60 min); and 112 received a matching
placebo infusion. The intravenous heparin and antiplatelet
regimens used have been described previously (4,13,14).
In all three studies, treatment with oral beta-adrenergic
blocking agents was commenced on days 2 to 3 in patients
without contraindications and, in the first study, intravenous
propranolol was recommended. In the third study, patients
were randomized to receive captopril or a matching placebo
2 h after commencing streptokinase therapy. Other medi-
cations such as calcium-channel blockers and nitrates were
prescribed only for postinfarction angina. All patients were
advised to stop smoking, lose weight, exercise regularly and
consume a low-fat diet.
Cardiac catheterization. In the absence of medically un-
controlled ischemia, angiography was performed three
weeks after infarction so as to minimize the confounding
effects of myocardial stunning (16) on ventricular volumes
and the ejection fraction (4,13,14). All patients received
sublingual nitrate before the procedure. Core laboratory
assessment (17) of infarct artery flow, blinded to treatment
and clinical outcome, was performed according to TIMI
flow grading (6) and the CTFC (9). The reproducibility of
the CTFC in our laboratory has been reported previously
(12). We prospectively determined CTFC cutpoints at 21,
15 and 27 (normal 6 2 SDs) and 40 (“quantitative” TIMI
grade 3) (18). Coronary artery stenoses and the number of
diseased vessels were determined according to the Coronary
Artery Surgery Study (CASS) criteria (19).
Follow-up. Patients underwent exercise testing using the
Bruce protocol at three weeks. Patients were reviewed every
three months for one year in the first two studies (4,13,14).
Late follow-up was performed either by recall to the clinic
or by telephone or mail contact with the patient or family
physician. End points were verified by source documenta-
tion. Deaths were classified as cardiac or noncardiac (20).
Reinfarction was defined as two of the following: prolonged
ischemic chest pain, an elevation in creatine kinase concen-
tration to more than two times normal or development of
new Q-waves on the electrocardiogram. Revascularization
was performed for severe angina not controlled by medical
therapy or $50% left mainstem stenosis detected by angiog-
raphy.
Statistical analysis. Baseline characteristics are expressed
as means 6 SDs or percentages. Continuous variables were
compared by one-way analysis of variance, and discrete
variables were compared by the chi-square test for indepen-
dence. Survival curves were constructed using the Kaplan-
Meier method and compared using the log-rank test. When
indicated, imputations for patients not undergoing angiog-
raphy were performed. The CTFC of occluded arteries was
assigned to patients dying early and the median CTFC was
assigned to surviving patients not undergoing angiography.
When indicated, the TIMI flow grades were imputed for
thrombolytic-treated patients with early death based on
GUSTO-I (2) and Heparin in Early Patency (HEAP)
studies (21) for those receiving heparin and aspirin only.
Using a conservative analytical approach, the highest CTFC
in a patent artery in this study (244) was assigned to
occluded arteries. Arteries graded TIMI 0 or 1 were
analyzed as occluded arteries. Univariate and multivariate
predictors of survival were identified using Cox
proportional-hazards regression methods, and the assump-
tion of proportional hazards was satisfied for variables in the
final models.
RESULTS
A total of 1,001 patients (mean age 57 6 9 years) were
randomized in the three trials to receive recombinant tissue
plasminogen activator (135), intravenous streptokinase
(754) or a matching placebo (112). Angiography was
performed on 882 patients (88%) at a median of 23 days
(interquartile range [IQR], 20 to 28).
The late mortality status was determined in 97.5% of
patients at a median of 6.3 years (IQR, 4.9 to 8.7 years).
There were 182 cardiac and 67 noncardiac deaths, and 86
nonfatal infarctions. Actuarial survival was 91% at one year,
82% at five years and 75% at 10 years (Fig. 1). Five-year
survival for the first two studies (1984 to 1988) was 81%,
Abbreviations and Acronyms
CASS 5 Coronary Artery Surgery Study
CTFC 5 corrected TIMI frame count
GISSI 5 Gruppo Italiano per lo Studio della
Sopravvivenza nell’Infarto Miocardico
GUSTO 5 Global Use of Strategies to Open Occluded
Coronary Arteries
HEAP 5 Heparin in Early Patency
IQR 5 interquartile range
TIMI 5 Thrombolysis in Myocardial Infarction
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and the third (1989 to 1994), 83% (p 5 0.40). Revascular-
ization at one, five and 10 years postinfarction was per-
formed in 12%, 19% and 23% of patients (133 surgical, 81
percutaneous), respectively. The event-free survival rates
(freedom from death, recurrent infarction or revasculariza-
tion) at five and 10 years were 64% and 55%, respectively
(Fig. 1).
Baseline clinical and angiographic characteristics are
shown in Tables 1 and 2. Of the 119 patients who did not
undergo angiography, 49 had died, 40 did not consent and
30 had significant comorbidity precluding angiography;
these patients are not further described herein, except where
indicated.
Infarct artery flow at three weeks. Seventy-four percent of
patients (644/882) had patent infarct-related arteries (TIMI
2 to 3 flow) at three weeks. The mean CTFC in patent
arteries was 40 6 29 (95% confidence interval, 38 to 42;
median 32 [IQR, 24 to 47]). Thirty-four percent of patients
had a CTFC of #27, 31% between 27 and 40, 30% between
40 and 100 (inclusive) and 4.4% had .100 (Fig. 2 and
Table 3).
The CTFC was a predictor of five-year survival, as did
TIMI flow grades (both p , 0.001) (Fig. 2). Survival curves
were similar for cardiac and total mortality and when only
those patients (786) receiving thrombolytic therapy were
analyzed (data not shown). Assessed as a continuous vari-
able, CTFCs correlated with cardiac death at one year
(chi-square 5 4.5; p 5 0.03) and five years (chi-square 5
6.5; p 5 0.01), but not at 10 years (chi-square 5 2.3; p 5
0.13) (Fig. 3).
Figure 1. Late actuarial outcome after myocardial infarction.
Table 1. Baseline Characteristics
Angiogram*
(n 5 882)
No Angiogram
(n 5 119)
p
Value
Total
(n 5 1,001)
Age (mean 6 SD) 56.7 6 9.2 61.3 6 9.8 ,0.001 57.2 6 9.3
Male gender 706 (80%) 77 (65%) 0.001 783 (78%)
Hypertension 228 (26%) 37 (35%) 0.055 265 (27%)
Diabetes mellitus 73 (8%) 14 (13%) 0.099 87 (9%)
Smoking 391 (44%) 42 (39%) 0.089 433 (44%)
Beta-blockers 127 (14%) 21 (21%) 0.068 148 (15%)
Cholesterol (mmol/liter) 6.2 6 1.2 6.14 6 1.1 0.65 6.2 6 1.2
LDL cholesterol (mmol/liter) 4.3 6 0.99 4.2 6 0.86 0.32 4.3 6 0.98
HDL cholesterol (mmol/liter) 0.97 6 0.31 0.99 6 0.31 0.012 0.99 6 0.31
Treatment
Streptokinase 662 (75%) 92 (77%) 754 (75%)
Tissue plasminogen activator 124 (14%) 11 (9%) 0.29 135 (14%)
Placebo 96 (11%) 16 (13%) } 112 (11%)
*Four patients had further intracoronary thrombolytic therapy with tissue plasminogen activator and four patients had angioplasty
on the day of hospital admission.
HDL 5 high-density lipoprotein; LDL 5 low-density lipoprotein.
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Patients with TIMI 3, TIMI 2 and TIMI 2 or 3 flow
were divided sequentially into groups at CTFC cut-points
of 15, 21, 27 and 40, respectively. There were no differences
in survival at one, five or 10 years in any group except for the
10-year survival of patients with TIMI 2 flow using a
CTFC cut-point of 21 (p 5 0.008). Among patients with
TIMI 3 flow, a CTFC cut-point of 21 was associated with
differences in the composite end point of death and recur-
rent myocardial infarction at 10 years (p 5 0.01). Among
patients with TIMI 2 or 3 flow, CTFC cut-points of 15 and
40 (three categoric groups) influenced the composite end
points of death or myocardial infarction and death or
myocardial infarction or revascularization (p , 0.01 for
both). Following imputations for deaths prior to angiogra-
phy, the CTFC (cut-point 40) in patients with TIMI 2 and
TIMI 2 or 3 flow predicted one-year survival (p , 0.05 for
both).
Ventricular function and the corrected TIMI frame
count. There was an association between an increasing
CTFC and an ejection fraction of ,50% (chi-square 5 8.6;
p 5 0.04). Similarly, an increased CTFC was associated
with an end-systolic volume index of $40 ml/m2 (chi-
square 5 10.7; p 5 0.014) (Table 3). Patients with occluded
arteries and either an ejection fraction of ,50% or an
end-systolic volume index of $40 ml/m2 had a lower
five-year survival rate than those with patent arteries (both
p , 0.05).
Predictors of late survival. On univariate analysis, the
predictors of survival at five years were age, ejection fraction,
end-systolic volume index, end-diastolic volume index,
treadmill exercise time, CTFC, TIMI flow grade (all p ,
0.001), diabetes and the number of stenosed vessels (both
p 5 0.002) and female gender (p 5 0.008) (Table 4). On
multivariate analysis, the end-systolic volume index or the
ejection fraction (both p , 0.001), treadmill exercise time
(p 5 0.005), diabetes (p 5 0.02) and the CTFC (p 5 0.02)
or TIMI flow grade (p 5 0.02) were predictors of five-year
survival (Table 5). The CTFC and TIMI flow grade
cosegregated in the multivariate model, and each factor,
when inserted separately in the five-factor model, had a p
value of 0.02. Imputations performed for patients dying
prior to angiography did not increase the p values for the
CTFC or TIMI flow grade. Factors predictive of 10-year
survival on multivariate analysis were the ejection fraction
(or end-systolic volume index), exercise time and age, but
not the CTFC or TIMI flow grade (Table 5).
DISCUSSION
In this study the CTFC, assessed at three weeks after
myocardial infarction, was an independent predictor of
five-year survival but not superior to TIMI flow grading.
Neither measure of infarct artery flow was a predictor of
10-year survival.
The TIMI flow grading after reperfusion therapy has
been accepted as the standard method of assessing infarct-
related artery blood flow (7). However, Gibson et al. (9)
highlighted discrepancies between infarct-related artery
flow assessments done at an angiographic core laboratory
Table 2. Angiographic Characteristics*
Placebo
(n 5 96)
Thrombolysis
(n 5 786)
Total
(n 5 882)
CTFC
#27 22 (23%) 198 (25%) 220 (25%)
27 to 40 16 (17%) 184 (23%) 200 (23%)
$40 to 244 20 (21%) 202 (25%) 222 (25%)
Occluded 37 (39%) 201 (26%) 238 (27%)
TIMI flow grade
0–1 37 (39%) 201 (26%) 238 (27%)
2 20 (21%) 142 (18%) 163 (18%)
3 39 (41%) 443 (56%) 481 (55%)
Infarct-related artery
Right coronary 54 (56%) 345 (44%) 399 (47%)
Left anterior descending 35 (36%) 326 (42%) 361 (42%)
Left circumflex 7 (7%) 107 (14%) 114 (13%)
Left ventricular function
Ejection fraction (%) 50.7 6 13.8 57.2 6 13.1 56.5 6 13.3
ESVI (ml/m2) 42.6 6 25.2 35.3 6 18.9 36.1 6 19.9
EDVI (ml/m2) 81.9 6 31.3 79.4 6 25.0 79.7 6 25.8
LVEDP (mm Hg) 16.0 6 8.4 15.3 6 8.0 15.4 6 8.0
*Comparisons between placebo and thrombolysis with respect to the CTFC, TIMI flow and infarct-related artery were p 5
0.044, p 5 0.008 and p 5 0.05, respectively, and between ventricular function characteristics EF, ESVI, EDVI and LVEDP:
p , 0.001, p 5 0.007, p 5 0.44 and p 5 0.49, respectively.
CTFC 5 corrected TIMI frame count; EDVI 5 end-diastolic volume index; ESVI 5 end-systolic volume index; LVEDP 5
left ventricular end-diastolic pressure; TIMI 5 Thrombolysis in Myocardial Infarction.
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Figure 2. Infarct-related artery flow in patients who underwent angiography at three weeks without imputation for early death. (A)
Comparison of CTFCs and TIMI flow grades. (B) Influence of CTFC on late survival. The log rank comparisons (four-way) at one, five
and 10 years were p 5 0.06, p 5 0.002 and p 5 0.26, respectively. (C) Influence of TIMI flow grades on late survival. The log rank
comparisons (three-way) at one, five and 10 years were p 5 0.03, p 5 0.0003 and p 5 0.14, respectively. The log rank comparisons
(two-way) between TIMI 3 and TIMI 0 to 1 and between TIMI 3 and TIMI 0 to 2 at one, five and 10 years were p 5 0.009, p 5 0.0001
and p 5 0.049; and p 5 0.025, p 5 0.004 and p 5 0.49, respectively. The log rank comparisons between TIMI 2 and TIMI 0 to 1 at
one, five and 10 years were p 5 0.25, p 5 0.047 and p 5 0.25, respectively. The log rank comparisons between TIMI 0 to 1 and TIMI
2 to 3 at one, five, and 10 years were p 5 0.012, p 5 0.0001 and p 5 0.049, respectively. There were no significant differences in survival
between patients with TIMI 2 and TIMI 3 flow. The results were similar when only thrombolytic-treated patients were analyzed (data
not shown). CTFC 5 corrected TIMI frame count; TIMI 5 Thrombolysis in Myocardial Infarction.
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and those done by local investigators, especially in patients
with TIMI 2 flow, where there was only 52% concordance.
To enhance reproducibility, these investigators developed
the CTFC as a more quantitative assessment of infarct-
related artery flow (9). We also found this method highly
reproducible (12).
In the present study, the CTFCs of patent infarct-related
arteries three weeks after infarction were prolonged (medi-
an, 32 [IQR, 24 to 47]), extending earlier observations that
have found the CTFC of patent arteries to be prolonged at
both 24 and 48 h after intravenous thrombolytic therapy
(9,11).
Infarct-related artery flow and outcome. The mechanism
of the early benefits of thrombolytic therapy has been
attributed to prompt restoration of blood flow in the
infarct-related artery, as measured by TIMI flow grading at
90 min (2,22). By 3 h, most thrombolytic regimens achieve
patency (TIMI 2 or 3 flow) in 70% to 80% of patients, and
the patency rate remains similar at one and three weeks
(2,4,22,23). In the current study, the CTFC at three weeks,
assessed as a continuous variable, independently predicted
total and cardiac mortality at five years, but not at 10 years.
The TIMI flow grade was also independently predictive
(p 5 0.02) and cosegregated with the CTFC. However,
CTFC, examined as a categoric variable in patients with
TIMI 2 or 3 flow, did influence the composite end points of
death or myocardial infarction and death or myocardial
infarction or revascularization. The TIMI group (18) has
also recently shown that the CTFC at 90 min, analyzed as
a categoric variable, was a predictor of one-month mortality,
and the composite end point of death, nonfatal infarction,
shock, heart failure or an ejection fraction of #40%.
The velocity of infarct artery flow needed to provide
sufficient myocyte nutrition to influence prognosis is un-
clear. We recently reported that survival in patients with
TIMI 2 flow may be interpreted as intermediate between
that of patients with TIMI 0 to 1 and TIMI 3 flow after
adjustment for baseline risk (24). In the current study,
patients with TIMI 2 flow had significantly better survival
rates than those with TIMI 0 to 1 flow, but not statistically
different than those with TIMI 3 flow. The TIMI flow
grade was a univariate predictor of five-year survival (p ,
0.001). The GUSTO investigators reported that the unad-
justed two-year survival of patients with TIMI 2 flow at
90 6 45 min was not significantly better than that of
patients with TIMI 0 to 1 flow (25). In the European
Cooperative Study (26), patients with TIMI 3 (but not
those with TIMI 2) flow at 10 to 22 days had a higher
survival rate at five years than patients with TIMI 0 to 1
flow.
The lack of influence of infarct artery flow on 10-year
survival may be due to several factors. These may include
progression of coronary artery disease in the infarct or
non–infarct-related arteries (as evidenced by the univariate
prognostic significance of the number of stenosed arteries),
plaque rupture or fissuring in non–infarct-related arteries,
late reocclusion with or without infarction, or the effect of
late revascularization. The possibility of beta error, the
increased incidence of late noncardiac deaths after five years,
the smaller numbers of patients followed up for 10 years, or
other unrecognized factors may also have influenced this
result.
Patency, ventricular function and survival. Left ventric-
ular function was the most powerful determinant of survival
at both five and 10 years, with the ejection fraction and
end-systolic volume index having similar influence. Two
studies have reported a relationship between the CTFC at
90 min and the ejection fraction, assessed either by predis-
charge radionuclide ventriculography or by 48-h contrast
ventriculography (9,11). At these times ejection fraction
may be influenced by myocardial stunning (16). We assessed
left ventricular function at three weeks after infarction when
myocardial stunning was likely to have resolved (11).
Other factors. The Gruppo Italiano per lo Studio della
Sopravvivenza Nell’Infarto Miocardico (GISSI) group (27)
has reported that exercise duration and inability to perform
an exercise test were powerful predictors of mortality at six
months. We found that exercise duration was independently
associated with both five- and 10-year outcomes. Lenderink
Table 3. Comparison Between Corrected TIMI Frame Counts, TIMI Flow and Ventricular Function at Three Weeks
CTFC
TIMI Flow*
Ventricular Function
ESVI (ml/kg/m2)† Ejection Fraction‡
3 2 0–1 Total <40 >40 <50% >50%
#27 205 15 — 220 152 (71%) 63 (29%) 50 (23%) 170 (77%)
27 to 40 174 26 — 200 138 (70%) 58 (30%) 47 (24%) 151 (76%)
$40 to 244 102 120 — 222 146 (67%) 72 (33%) 69 (31%) 152 (69%)
Occluded arteries — — 238 238 135 (58%) 98 (42%) 76 (32%) 158 (68%)
Total 479 161 238 880§ 571 291 243 631
Data represent the number of patients in each category. *Comparison of CTFC (four categories) with TIMI flow chi-square 5 1099.5; p , 0.001. †Comparison of CTFC (four
categories) and end-systolic volume index chi-square 5 10.7; p 5 0.014. ‡Comparison of CTFC (four categories) and ejection fraction chi-square 5 8.6; p 5 0.04. §CTFC could
not be assessed in two patients with coronary artery dissection.
CTFC 5 corrected TIMI frame count; ESVI 5 end-systolic volume index (ml/kg/m2); TIMI 5 Thrombolysis in Myocardial Infarction.
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Figure 3. Influence of the CTFC on cardiac death. (A) At one year. (B) At five years. (C) At 10 years. The cumulative frequency is the
percentage of patients with a CTFC not exceeding the X-value. CTFC 5 corrected TIMI frame count; TIMI 5 Thrombolysis in
Myocardial Infarction.
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et al. (26) also found that exercise duration at hospital
discharge influenced five-year survival. Neither baseline
total nor high density lipoprotein cholesterol levels influ-
enced late outcome, possibly due to beta error, the effects of
dietary advice or pharmacologic therapy.
Study limitations. The effect of the CTFC, measured in
the early hours and days postinfarction, was not examined in
the present study. The CTFC measured at 90 min may have
had a greater effect on late mortality than has been reported
herein, as approximately 20% of deaths occurred prior to
angiography, although imputation of infarct artery flow for
these early deaths did not influence these findings. While
CTFC provided additional prognostic information within
the TIMI flow grade, our study may have been underpow-
ered to determine whether the CTFC was a better predictor
of late survival than the TIMI flow grade.
The CTFC at three weeks represented the net effects of
Table 4. Univariate Predictors of Late Mortality
5 y 10 y
Chi-square p* Value Chi-square p* Value
Clinical factors
Age 33.7 ,0.001 49.6 ,0.001
Female gender 7.3 0.008 6.0 0.01
Diabetes 10.1 0.002 11.0 ,0.001
Hypertension 3.6 0.06 1.4 0.25
Smoking 1.12 0.29 3.5 0.06
Total cholesterol (mmol/liter) 0.82 0.36 2.3 0.13
HDL cholesterol (mmol/liter) 2.3 0.13 0.1 0.75
Exercise time 23.7 ,0.001 25.6 ,0.001
Angiographic factors
Ejection fraction 29.4 ,0.001 63.9 ,0.001
ESVI 31.9 ,0.001 49.8 ,0.001
EDVI 16.7 ,0.001 19.8 ,0.001
TIMI flow 14.9 ,0.001 3.6 0.06
CTFC† 13.9 ,0.001 2.6 0.11
No. of stenosed vessels 9.3 0.002 13.2 ,0.001
IRA5LAD 0.9 0.35 0.17 0.68
*No adjustments have been made for multiple comparisons. †CTFC of occluded arteries imputed at the maximum value of patent
arteries (244).
CTFC 5 corrected TIMI frame count; EDVI 5 end-diastolic volume index; ESVI 5 end-systolic volume index; HDL 5
high-density lipoprotein; IRA5LAD 5 infarct related artery-left anterior descending coronary artery; TIMI 5 Thrombolysis
in Myocardial Infarction.
Table 5. Multivariate Predictors of Late Mortality
Variables
p
(Coefficient)
Chi-square
(Model)
df
(Model)
p
(Model)
5-yr mortality
Age 0.008 65 5* ,0.001
Exercise time 0.005
Ejection fraction† ,0.001
CTFC‡ 0.02
Diabetes 0.02
10-yr mortality
Age ,0.001 99 5 ,0.001
Exercise time 0.01
Ejection fraction† ,0.001
CTFC‡ 0.82
Diabetes 0.02
*Number of diseased vessels (p 5 0.1) in six-factor model. †p and chi-square values were similar for the model if end-systolic
volume index was substituted for ejection fraction. The end-systolic volume index was the most powerful predictor of five-year
survival, and the ejection fraction was more powerful at 10 years. ‡p 5 0.02 and 0.78 for TIMI flow if this factor was substituted
for CTFC as a predictor of five- and 10-year mortality, respectively. Insertion of CTFC as a three-way categoric variable (similar
to TIMI flow grades) did not increase the p value.
CTFC 5 corrected TIMI frame count; df 5 degrees of freedom; TIMI 5 Thrombolysis in Myocardial Infarction.
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reperfusion and reocclusion in patients treated with aspirin
(with or without dipyridamole), intravenous heparin admin-
istered for 48 h, and either streptokinase (administered over
30 to 60 min) or recombinant tissue plasminogen activator
(administered over 3 h) or a placebo.
A conservative approach to revascularization was under-
taken in the absence of left main stenosis or limiting
symptoms. In the present study, only 12% of patients had
undergone revascularization at one year and 23% at 10 years,
compared with approximately 20% at one year in the
European Cooperative Study (26). The value of the CTFC
as a predictor of late survival may be different with higher or
lower rates of revascularization.
CONCLUSIONS
The CTFC at three weeks after infarction is an independent
predictor of five-year mortality, and provides a more repro-
ducible assessment of flow in patent infarct arteries than the
TIMI flow grade. Further studies are necessary to determine
whether the CTFC should influence prognostic decisions
regarding revascularization or medical therapies.
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